Encorafenib with cetuximab for patients with BRAF V600E variants

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[55] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following regimens: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[56]

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[55] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following regimens: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[56]

Triplet therapy: encorafenib (300 mg PO daily), binimetinib (45 mg PO twice daily), and cetuximab (400 mg/m2 IV loading dose followed by 250 mg/m2 IV weekly) (n = 224).

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[55] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following regimens: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[56]

Doublet therapy: encorafenib and cetuximab (as per triplet therapy dosing) (n = 220).

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[55] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following regimens: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[56]

Control group: FOLFIRI or irinotecan (every 2 weeks) with cetuximab (400 mg/m2 IV loading dose followed by 250 mg/m2 IV weekly) (n = 221).

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[55] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following regimens: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[56]

The OS was 9.0 months in the triplet-therapy arm and 5.4 months in the control group (HR, 0.52; 95% CI, 0.39–0.70, P < .0001).[55][Level of evidence A1]

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[55] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following regimens: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[56]

Grade 3 or higher side effects occurred in 58% of patients in the triplet-therapy arm, with 10% of patients experiencing diarrhea and 11% of patients experiencing anemia. Grade 3 or higher side effects occurred in 50% of patients in the doublet-therapy arm and 61% of patients in the control arm. Fourteen percent of patients who received the doublet regimen developed melanocytic nevi.

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[55] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following regimens: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[56]

The median OS was 9.3 months in both the triplet-therapy and doublet-therapy arms and 5.9 months in the control arm (HR, 0.60 for triplet therapy vs. control; 95% CI, 0.47–0.75; HR, 0.61 for doublet therapy vs. control; 95% CI, 0.48–0.77).

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[55] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following regimens: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[56]

The objective response rate was 26.8% for patients who received triplet therapy (95% CI, 21.1%–33.1%) and 19.5% for patients who received doublet therapy (95% CI, 14.5%–